Generic Weight Loss Drugs: Semaglutide Patent Expiration to Lower Costs and Increase Access

The patent for semaglutide, the active ingredient in blockbuster drugs like Ozempic and Wegovy, expired on March 20, 2026, paving the way for nearly 50 generic brands to enter the market. This development is expected to significantly increase access to these medications and lower costs, potentially by at least a third, according to market experts.

What to Expect with Generic Semaglutide

The new generic products are anticipated to launch at prices ranging from one-third to one-fifth the cost of the original brand-name drugs, earning them the nicknames “generic Ozempic” and “generic Wegovy.” Several major pharmaceutical companies, including Dr. Reddy’s, Zydus, Sun Pharmaceuticals, Cipla, and Lupin, are entering the market. This competition is projected to bring the monthly cost of a once-weekly semaglutide injectable down to between Rs 3,000 and Rs 4,000 in India.

Currently, Ozempic costs between Rs 8,800 and Rs 11,175 per month, depending on the dosage (0.25 mg, 0.5 mg, and 1 mg), whereas Wegovy ranges from Rs 10,850 to Rs 16,400. Generics will be equivalent to brand-name drugs in dosage, safety, strength, quality, and performance, but without the expense of repeating costly clinical trials.

Why Semaglutide is in Demand

Semaglutide’s popularity stems from its ability to mimic the effects of the GLP-1 hormone, which is released in the gut after eating. This hormone stimulates insulin production, lowers blood sugar, slows digestion, and reduces appetite. Initially approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of Type 2 diabetes, semaglutide quickly gained off-label use as a weight-loss agent. A higher-dose version was subsequently approved by the FDA for weight loss in 2021.

Novo Nordisk, the original patent holder, markets Ozempic for Type 2 diabetes and Wegovy specifically for chronic obesity. Both drugs were launched in India last year prior to the patent expiration.

Mounjaro and Tirzepatide: A Different Landscape

While semaglutide faces increased competition with the arrival of generics, Eli Lilly’s tirzepatide drug, Mounjaro, remains protected by a patent that doesn’t expire until 2035. Tirzepatide mimics both GLP-1 and another hormone, GIP, and currently commands 61% of the Indian weight loss market. Eli Lilly has partnered with Cipla to sell branded tirzepatide, while Biocon is developing injectables expected to launch in 2027.

The Indian Market Outlook

Despite the entry of nearly 50 brands, industry analysts predict that only three or four major players will capture a significant market share. Smaller companies’ brands, with limited physician prescribing, are expected to fade. This pattern has been observed with other diabetes drugs that have come off patent.

Novo Nordisk and Eli Lilly, the current market leaders, are not expected to alter their pricing strategies significantly. Novo Nordisk stated that their approach is “driven by patients, not patents,” emphasizing the strong clinical evidence base supporting semaglutide, with over 50 robust clinical trials and 49 million patient years of exposure.

Impact on Existing Patients and New Users

While generics may erode some of Mounjaro’s market share, a rapid shift is unlikely. Patients already using Mounjaro or Wegovy, who can afford these medications, may be hesitant to switch to generics immediately, valuing the established quality and avoiding potential initial side effects associated with a new product.

Yet, lower-cost generics are expected to significantly increase the number of people using GLP-1 therapy, including those previously deterred by the high price. Experts predict a two-to-threefold surge in usage as affordability and awareness of diabetes and obesity management increase.

Alkem Laboratories, set to launch its generic version of semaglutide upon patent expiration, anticipates that generics will capture a larger volume share as GLP-1 therapy becomes more accessible.

Innovations in Delivery and Market Strategies

Drug manufacturers are exploring innovations to gain a competitive edge. Zydus Lifesciences plans to launch semaglutide pens that can be used multiple times, allowing patients to select and administer varying dose strengths from a single unit. This feature simplifies the titration process (gradually increasing the dose), as current pens dispense only a single dosage.

Addressing Misuse and Ensuring Responsible Use

The popularity of GLP-1 drugs, fueled by celebrity endorsements, has raised concerns about potential misuse. Companies are actively engaging in marketing and “awareness campaigns,” prompting a warning from the Central Drugs Standard Control Organisation (CDSCO) against promotional activities that create brand recall or product visibility.

The All-India Chemists and Druggists Association has instructed its members to dispense these products only with a doctor’s prescription, addressing reports of Mounjaro being sold without one. Novo Nordisk as well emphasizes the importance of avoiding self-medication and misuse.

While semaglutide has a generally favorable safety profile, it can cause adverse effects like nausea, vomiting, and gastrointestinal symptoms, particularly when starting treatment. More serious side effects, such as pancreatitis, thyroid cancer, and stomach paralysis, are also possible. Responsible use, under appropriate medical supervision, is crucial, distinguishing between medical obesity management and cosmetic weight loss.